Novo Nordisk ADR [NYSE: NVO] closed the trading session at $124.53.
The stocks have a year to date performance of 20.38 percent and weekly performance of -0.32 percent. The stock has been moved at 23.11 percent over the last six months. The stock has performed -6.29 percent around the most recent 30 days and changed 16.73 percent over the most recent 3-months.
If compared to the average trading volume of 5.04M shares, NVO reached to a volume of 3070801 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novo Nordisk ADR [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $134.59 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 1.94. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Novo Nordisk ADR shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 12, 2024. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on January 23, 2024, representing the official price target for Novo Nordisk ADR stock.
The Average True Range (ATR) for Novo Nordisk ADR is set at 2.61, with the Price to Sales ratio for NVO stock in the period of the last 12 months amounting to 12.50. The Price to Book ratio for the last quarter was 26.68, with the Price to Cash per share for the same quarter was set at 1.32. Price to Free Cash Flow for NVO in the course of the last twelve months was 34.94 with Quick ratio for the last quarter at 0.64.
NVO stock trade performance evaluation
Novo Nordisk ADR [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.32. With this latest performance, NVO shares dropped by -6.29% in over the last four-week period, additionally plugging by 23.11% over the last 6 months – not to mention a rise of 45.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVO stock in for the last two-week period is set at 45.63, with the RSI for the last a single of trading hit 42.51, and the three-weeks RSI is set at 49.05 for Novo Nordisk ADR [NVO]. The present Moving Average for the last 50 days of trading for this stock 125.96, while it was recorded at 124.36 for the last single week of trading, and 103.35 for the last 200 days.
Novo Nordisk ADR [NVO]: An insightful look at the core fundamentals
Novo Nordisk ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.64 and a Current Ratio set at 0.82.
Earnings per share (EPS) analysis for Novo Nordisk ADR [NVO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk ADR go to 2.80%.
Novo Nordisk ADR [NVO]: Institutional Ownership
The top three institutional holders of NVO stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in NVO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in NVO stock with ownership which is approximately 5.8386%.
